EUVIMEDEUVIMED entdecken
Crossref

Evaluating the Utility of 18 F-FDG PET/CT in Cancer of Unknown Primary

Tharani Sivakumaran, Anthony Cardin, Jason Callahan, Hui-Li Wong, Richard W Tothill, Rodney J Hicks, Linda R Mileshkin

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.267274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Tharani Sivakumaran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; tharani.sivakumaran@petermac.org. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Neoplasms, Unknown Primary. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumors for which standardized diagnostic work-up fails to identify the primary site. We aimed to describe the Peter MacCallum Cancer Centre experience with 18F-FDG PET/CT in extracervical CUP with respect to detection of a primary site and its impact on management. A secondary aim was to compare overall survival (OS) in patients with and without a detected primary site.

Methods

CUP patients treated between 2014 and 2020 were identified from medical oncology clinics and 18F-FDG PET/CT records. Information collated from electronic medical records included the suspected primary site and treatment details before and after 18F-FDG PET/CT. Clinicopathologic details and genomic analysis were used to determine the clinically suspected primary site and compared against 2 independent masked reads of 18F-FDG PET/CT images by nuclear medicine specialists to determine sensitivity, specificity, accuracy, and the rate of detection of the primary site.

Results

We identified 147 patients, 65% of whom had undergone molecular profiling. The median age at diagnosis was 61 y (range, 20-84 y), and the median follow-up time was 74 mo (range, 26-83 mo). Eighty-two percent were classified as having an unfavorable CUP subtype as per international guidelines.18F-FDG PET/CT demonstrated a primary site detection rate of 41%, resulted in a change in management in 22%, and identified previously occult disease sites in 37%. Median OS was 16.8 mo for all patients and 104.7 and 12.1 mo for favorable and unfavorable CUP subtypes, respectively (P < 0.0001). Median OS in CUP patients when using 18F-FDG PET/CT, clinicopathologic, and genomic information was 19.8 and 8.5 mo when a primary site was detected and not detected, respectively (P = 0.016). Multivariable analysis of survival adjusted for age and sex remained significant for identification of a potential primary site (P < 0.001), a favorable CUP (P < 0.001), and an Eastern Cooperative Oncology Group status of 1 or less (P < 0.001).

Conclusion

18F-FDG PET/CT plays a complementary role in CUP diagnostic work-up and was able to determine the likely primary site in 41% of cases. OS is improved with primary site identification, demonstrating the value of access to diagnostic 18F-FDG PET/CT for CUP patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18Neoplasms, Unknown PrimaryHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overYoung AdultRetrospective Studies

Stichwörter der Autor:innen

18F-FDG PET/CTcarcinoma of unknown primaryoverall survival

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; tharani.sivakumaran@petermac.org.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Melbourne Theranostic Innovation Centre, Melbourne, Victoria, Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Clinical Pathology and University of Melbourne Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia; and.

Zitieren

APA

Sivakumaran, T., Cardin, A., Callahan, J., Wong, H. L., Tothill, R. W., Hicks, R. J., & Mileshkin, L. R. (2024). Evaluating the Utility of 18 F-FDG PET/CT in Cancer of Unknown Primary. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267274

Vancouver

Sivakumaran T, Cardin A, Callahan J, Wong HL, Tothill RW, Hicks RJ, et al. Evaluating the Utility of 18 F-FDG PET/CT in Cancer of Unknown Primary. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267274

BibTeX
@article{Sivakumaran2024,
  author = {Sivakumaran, Tharani and Cardin, Anthony and Callahan, Jason and Wong, Hui-Li and Tothill, Richard W and Hicks, Rodney J and Mileshkin, Linda R},
  title = {Evaluating the Utility of 18 F-FDG PET/CT in Cancer of Unknown Primary},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.267274}
}
Kostenlos starten →